- Marker Therapeutics Inc to Participate in the Beyond CAR-T: What's Next for Cell Therapy Event TranscriptAug 09, 2023
- Marker Therapeutics Inc to Host Clinical Program Update Call TranscriptFeb 16, 2022
- Marker Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Q1 2021 Marker Therapeutics Inc Earnings Call TranscriptMay 12, 2021€19.1 (-1.04%)Earnings
- Q3 2020 Marker Therapeutics Inc Earnings Call TranscriptNov 09, 2020€12.7 (+8.55%)Earnings
- Marker Therapeutics Inc MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting TranscriptJun 01, 2020
- Q1 2020 Marker Therapeutics Inc Earnings Call TranscriptMay 11, 2020€22.8 (+8.57%)Earnings
- Q3 2019 Marker Therapeutics Inc Earnings Call TranscriptNov 12, 2019€35.64 (-0.03%)Earnings
- Marker Therapeutics Inc Special Call TranscriptJul 22, 2019
- Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 16, 2019
Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
(technical difficulty)
Hoang, I'm the President and Chief Executive Officer of Marker Therapeutics. It's our great pleasure as a company to be able to present here today and tell you a little bit about what we have been doing as a company. So we should have our presentation projected momentarily here. Let me just say that we're a public company, and so I encourage you to refer to our public filings for a comprehensive list of risk factors as we will be making forward-looking statements today.
So Marker Therapeutics is, I think, a very, very different cell therapy company from most of the cell therapy companies that are advancing products in immuno-oncology today. In that what we are creating is a multi-antigen specific product that targets not only a single epitope of a single-target antigen, but potentially multiple target epitopes. In fact, our product seeks to create an omni epitope product across up to 5 tumor-associated antigens. In fact, our current products average around 4,000 different T cell clonotypes.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)